Header

UZH-Logo

Maintenance Infos

Transient efficacy of Tofacitinib in Alopecia Areata Universalis


Anzengruber, Florian; Maul, Julia-Tatjana; Kamarachev, Jivko; Trüeb, Ralph M; French, Lars E; Navarini, Alexander A (2016). Transient efficacy of Tofacitinib in Alopecia Areata Universalis. Case Reports in Dermatology, 8(1):102-106.

Abstract

Alopecia areata is a common autoimmune disorder that targets hair follicles. Swarms of lymphocytes surround the basis of the follicles, inducing loss of pigmented terminal hair and subsequently inhibit further hair growth. Depending on the extent of involvement, alopecia areata can be associated with a dramatic reduction of quality of life. Currently, no targeted treatment option is available, and topical immune therapies or immunosuppressive drugs are typically used with mixed success. Recently, several cases of alopecia areata responding to Janus kinase inhibitors were published. Here, we report on a businessman with alopecia areata universalis who was treated with tofacitinib. We observed initial signs of hair regrowth in the same timeframe as previously reported, but efficacy quickly waned again, leading to renewed effluvium. Thus, even though tofacitinib and ruxolitinib are a promising new treatment option, we have yet to learn more about their potential role in each particular patient's individual treatment strategy.

Abstract

Alopecia areata is a common autoimmune disorder that targets hair follicles. Swarms of lymphocytes surround the basis of the follicles, inducing loss of pigmented terminal hair and subsequently inhibit further hair growth. Depending on the extent of involvement, alopecia areata can be associated with a dramatic reduction of quality of life. Currently, no targeted treatment option is available, and topical immune therapies or immunosuppressive drugs are typically used with mixed success. Recently, several cases of alopecia areata responding to Janus kinase inhibitors were published. Here, we report on a businessman with alopecia areata universalis who was treated with tofacitinib. We observed initial signs of hair regrowth in the same timeframe as previously reported, but efficacy quickly waned again, leading to renewed effluvium. Thus, even though tofacitinib and ruxolitinib are a promising new treatment option, we have yet to learn more about their potential role in each particular patient's individual treatment strategy.

Statistics

Citations

Dimensions.ai Metrics
19 citations in Web of Science®
19 citations in Scopus®
17 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

511 downloads since deposited on 25 Apr 2016
27 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:April 2016
Deposited On:25 Apr 2016 16:13
Last Modified:02 Feb 2018 09:57
Publisher:Karger
ISSN:1662-6567
OA Status:Gold
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1159/000445182

Download

Download PDF  'Transient efficacy of Tofacitinib in Alopecia Areata Universalis'.
Preview
Content: Published Version
Language: English
Filetype: PDF
Size: 665kB
View at publisher
Licence: Creative Commons: Attribution 4.0 International (CC BY 4.0)